Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ERNA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
globenewswire.com
9 hours ago
Relative Strength
ERNA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.07Ā ( -5.22%)
Pre-market 1.24$
0.06 (5.08%)
Relative Strenght
4
Volume Buzz
2%
Earning Acce
No
Dist 52w H.
95%Quote Panel
Key Metrics
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-1.06
vsĀ -3.40
Q2.23
N/A
-0.85
vsĀ -1.20
Q3.23
N/A
-1.03
vsĀ -2.49
Q4.23
N/A
-1.14
vsĀ -1.24
Q1.24
N/A
-1.23
vsĀ -1.06
Q2.24
N/A
-1.02
vsĀ -0.85
Q3.24
N/A
-4.92
vsĀ -1.03
Q4.24
N/A
-1.14
vsĀ -1.14
Q1.25
N/A
-2.25
vsĀ -1.23
Q2.25
N/A
-0.61
vsĀ -1.02
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NAĀ vsĀ NA
Q2.23
NA
NAĀ vsĀ NA
Q3.23
NA
51KĀ vsĀ NA
Q4.23
NA
17KĀ vsĀ NA
Q1.24
NA
47KĀ vsĀ NA
Q2.24
NA
47KĀ vsĀ NA
Q3.24
+855%
487KĀ vsĀ 51K
Q4.24
-94%
1KĀ vsĀ 17K
Q1.25
-100%
NAĀ vsĀ 47K
Q2.25
-100%
NAĀ vsĀ 47K
Return on Equity
QoQ
Q1.23
-73%
-0.73
vsĀ -0.37
Q2.23
-117%
-1.17
vsĀ -0.73
Q3.23
-157%
-1.57
vsĀ -1.17
Q4.23
-276%
-2.76
vsĀ -1.57
Q1.24
+195%
1.95
vsĀ -2.76
Q2.24
+65%
0.65
vsĀ 1.95
Q3.24
+59%
0.59
vsĀ 0.65
Q4.24
-339%
-3.39
vsĀ 0.59
Q1.25
+138%
1.38
vsĀ -3.39
Q2.25
-71%
-0.71
vsĀ 1.38
Institutionnal Ownership
QoQ
Q4.22
18
18
vsĀ NA
NA
Q1.23
19
19
vsĀ 18
6%
Q2.23
19
19
vsĀ 19
NA
Q3.23
19
19
vsĀ 19
NA
Q4.23
19
19
vsĀ 19
NA
Q1.24
22
22
vsĀ 19
16%
Q2.24
19
19
vsĀ 22
-14%
Q3.24
20
20
vsĀ 19
5%
Q4.24
24
24
vsĀ 20
20%
Q1.25
26
26
vsĀ 24
8%
Forecast
2026-Revenue
-28916%2026-EPS
703%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
No Data Available